Medications and lab tests arent included in this price
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) not yet licensed by the MHRA or EMA for use in the UK
they're easy traps for even experienced researchers to fall into during a busy day
My guess would be sometime in mid to late 2026 if they dont experience any hurdles in trial completion
READ NEXT: 8 ways to save money on Ozempic Overweight & obesity statistics, National Institute of Diabetes and Digestive and Kidney Diseases (2021) Adult obesity facts, Centers for Disease Control and Prevention How overweight and obesity affects your health, Centers for Disease Control and Prevention Polycystic ovary syndrome, World Health Organization Obesity and polycystic ovary syndrome: Implications for pathogenesis and novel management strategies, Clinical Medicine Insights: Reproductive Health (2019) Polycystic ovary syndrome (PCOS), Cleveland Clinic (2023) Weight management interventions in women with and without PCOS: A systematic review, Nutrients (2017) Medications containing semaglutide marketed for type 2 diabetes or weight loss, U.S
Timper K, Del Ro-Martn A, Cremer AL, Bremser S, Alber J, Giavalisco P, et al
